Repare Therapeutics Inc (RPTX)

Dec 19, 2024

From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca

Dec 19, 2024

Dec 15, 2024

Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World

Dec 15, 2024

Dec 15, 2024

Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World

Dec 15, 2024

Dec 14, 2024

Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat

Dec 14, 2024

Dec 14, 2024

LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN

Dec 14, 2024

Dec 13, 2024

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga

Dec 13, 2024

Dec 13, 2024

Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance

Dec 13, 2024

Dec 13, 2024

Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online

Dec 13, 2024

Dec 13, 2024

Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance

Dec 13, 2024

Dec 13, 2024

Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Dec 13, 2024

Dec 13, 2024

Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com

Dec 13, 2024

Dec 13, 2024

Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat

Dec 13, 2024

Dec 13, 2024

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Dec 13, 2024

Dec 12, 2024

Promising trial results for Repare's cancer drug combo - Investing.com India

Dec 12, 2024

Dec 12, 2024

Repare stock tanks 38% after Phase 1 data release - MSN

Dec 12, 2024

Dec 12, 2024

Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK

Dec 12, 2024

Dec 12, 2024

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire

Dec 12, 2024

Dec 12, 2024

Repare Therapeutics' Cancer Drug Combo Shows Strong 37.5% Response Rate in Advanced Ovarian Cancer Trial - StockTitan

Dec 12, 2024

Dec 11, 2024

Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News

Dec 11, 2024

Dec 10, 2024

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - BioSpace

Dec 10, 2024

Dec 10, 2024

UK desirability has turned a corner in clinical trials - Yahoo Finance

Dec 10, 2024

Dec 10, 2024

Repare Therapeutics to Present Phase 1 Cancer Trial Data for Novel Drug Combination in December - StockTitan

Dec 10, 2024

Nov 13, 2024

Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St

Nov 13, 2024

Nov 13, 2024

Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance

Nov 13, 2024

Nov 13, 2024

Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics partners with NCI on cancer drug - Investing.com India

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 08, 2024

Nov 08, 2024

Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks

Nov 08, 2024

Nov 07, 2024

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News

Nov 07, 2024

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 25, 2024

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo Finance

Oct 25, 2024

Oct 24, 2024

Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 24, 2024

Oct 24, 2024

Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News

Oct 23, 2024

Oct 23, 2024

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace

Oct 23, 2024

Oct 23, 2024

Repare Therapeutics reports progress in cancer trial - Investing.com India

Oct 23, 2024

Oct 19, 2024

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN

Oct 19, 2024

Oct 16, 2024

Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Oct 16, 2024

Oct 14, 2024

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News

Oct 14, 2024

Oct 14, 2024

Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices

Oct 14, 2024

Oct 14, 2024

Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia

Oct 14, 2024